Andrew M. Rogers
Tufts University · 33 works · 7,820 citations · h-index 15
Top works
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer
- Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
- Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
- Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients
- Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers
- Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors
- A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples
- c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential
- Acquired Gitelman Syndrome Secondary to Bendamustine Use.
- miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential
- Transformed cell-specific induction of apoptosis by porcine circovirus type 1 viral protein 3
- Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma
- BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL
- Comparison of genotyping with direct sequencing as a method to detect EGFR mutations in NSCLC
- Mass Cytometry as a Tool for Investigating Senescence in Multiple Model Systems
- Abstract 4736: Amplification of ERK2 mediates resistance to the novel irreversible EGFR inhibitor WZ4002